$PCSA If you followed my recent call on $IMNM at $14 just a seek ago, it may be worth taking a good look at Processa here. You are buying it under what Peter Appel and a handful of us paid months back when we gave them over $7M. Very compelling asymmetric risk here. Risking maybe $1 with upside of $40 plus, with just one of a handful of their pipeline assets being successful. Remember, this team previously sold their last company for $5.6B and they have an extensive history with the FDA consisting of over 100 interactions related to over 50 products and approximately 30 approvals across nearly every division of the agency.